leisure time -WSS

leisure time

author：leisure time 2025-09-06 05:03:06 - browse：75631

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： New weight loss drugs work. But how can they best be used?

leisure time

WSS

The biotech scorecard for Q1: 17 stock

J&J to buy cancer drug developer Ambrx Biopharma

Evacuations in place as 3 wildfires burn in eastern Washington state

Goldman Sachs launches $650M fund for life science investments

Videos point to link between seizures and unexplained toddler deaths

Morgan Health, with ambitious aims, wants you to know it’s still here

hotspot

leisure time

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Trump cancels press conference intended to dispute Georgia election interference charges

Sports medicine is finally prioritizing gender equality

AdventHealth escalates lawsuit against insurance vendor Multiplan

Bright Health sells Medicare Advantage business to Molina

A single drug, study failures leave Anavex with nothing but cash

Trump demands the U.S. pay no more for drugs than other countries … again

Evacuations in place as 3 wildfires burn in eastern Washington state

The cancer drug shortage isn’t new — and neither are the solutions

Eye stem cell transplant could help restore vision in injured people

explore

Hilary may become 1st tropical storm to make landfall in California in 84 years

Patient advocates sound warning on FDA proposal on salt intake

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

A single drug, study failures leave Anavex with nothing but cash

New details revealed about Purdue's marketing of OxyContin

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

entertainment

hotspot

leisure time

explore